Low serum albumin is an independent risk factor in elderly patients with aggressive B-cell lymphoma: Results from prospective trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.

Serum albumin a well-known risk factor predicting outcome in many solid tumors. We explore the role of low serum albumin (≤3.5 g/dL) as an independent risk factor in elderly patients with aggressive B-cell lymphoma. Outcome of 429 patients treated with R-CHOP-14 in the RICOVER-60 trial and available serum albumin were analyzed in this retrospective study. Of the 429 patients in the RICOVER-60 trial, 137 (32%) had low and 292 (68%) had normal serum albumin levels (>3.5 g/dL). In the low albumin group, patients had significantly higher International Prognostic Index (IPI), bulky disease, extralymphatic involvement, and B-symptoms. Event-free survival (EFS) ( < .001), progression-free survival (PFS) ( < .001), and overall survival (OS) ( < .001) were significantly inferior for patients with low compared to those with normal serum albumin. Multivariate analysis adjusted for IPI shows following Hazard ratios (HR) for low serum albumin: EFS (HR = 1.5; 95% confidance interval [CI] [1.1; 2.1],  = .009), PFS (HR = 1.7; 95% CI [1.2; 2.4],  = .001) and OS (HR = 1.6; 95% CI [1.1; 2.3],  = .006). Results were confirmed in 185 patients from the DENSE-R-CHOP-14 and SMARTE-R-CHOP-14 trials. In conclusion, low serum albumin is an independent risk factor in elderly patients with aggressive B-cell lymphoma treated with R-CHOP.